Drugs / AmnioPul-02
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05348772 Comparator | Oct 2022 → Feb 2023 | COVID-19 | Amniotics AB | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AmnioPul-02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05348772 ↗ |
| Modality | Cell therapy | “Novel Somatic Cell Therapy, AmnioPul-02” NCT05348772 ↗ |